Fig. 1

TRIM33 deficiency resulted in cell-intrinsic impairments of DC homeostasis and development. A–D Flow cytometry analysis of DC populations in Trim33^fl/fl and Trim33^fl/fl Itgax-Cre mice. The samples in (A) were enriched for DCs, and viable cells were pregated. MLN: mesenteric lymph node, SLN: subcutaneous lymph node. B, D Numbers of splenic CD11c^intSiglecH⁺ pDCs, CD11c⁺SiglecH^–CD24⁺CD172α^– cDC1s, and CD11c⁺SiglecH^–CD24^–CD172α⁺ cDC2s; thymic CD11c^intB220⁺ pDCs, CD11c⁺B220^–CD24⁺CD172α^– cDC1s, and CD11c⁺B220^–CD24^–CD172α⁺ cDC2s; and lymph node B220⁺PDCA-1⁺ pDCs (Fig. S2A), CD3ε^–CD19^–F4/80^–/loCD11c⁺MHC-II^hi migratory DCs (mDCs), and CD3ε^–CD19^–F4/80^–/loCD11c^hiMHC-II⁺ resident DCs (rDCs). E-G Flow cytometry analysis of splenic DCs and BM pDCs from tamoxifen-treated Trim33^fl/fl and Trim33^fl/fl Cre-ER^T2 mice. DC-enriched splenocytes were pregated for viable cells, and BM cells were pregated for viable CD11b^–CD19^– cells. Plots in (F) show the numbers of splenic pDCs, SiglecH^–CD11c⁺CD8α⁺CD172α^– cDC1s, SiglecH^–CD11c⁺CD8α^–CD172α⁺ cDC2s, and SiglecH⁺CD11c⁺ BM pDCs. G Numbers of BM and splenic CD19⁺ cells. N = 4–5. H, I Flow cytometry analysis of CD45.2⁺ populations in the indicated BM-reconstituted mice. Mice were treated with tamoxifen 3 weeks after reconstitution. Viable CD45.2⁺ cells were gated as described in (E). N = 4–6. The numbers on the plots indicate percentages. The absolute cell number per animal is shown. Bars represent the means ± SEMs. Representative data from 2 to 3 independent experiments are shown. The data were analyzed using two-tailed Student’s t tests. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001